JP2011506497A5 - - Google Patents

Download PDF

Info

Publication number
JP2011506497A5
JP2011506497A5 JP2010538345A JP2010538345A JP2011506497A5 JP 2011506497 A5 JP2011506497 A5 JP 2011506497A5 JP 2010538345 A JP2010538345 A JP 2010538345A JP 2010538345 A JP2010538345 A JP 2010538345A JP 2011506497 A5 JP2011506497 A5 JP 2011506497A5
Authority
JP
Japan
Prior art keywords
rhoc
seq
item
peptide fragment
amino acids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010538345A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011506497A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/DK2008/050324 external-priority patent/WO2009076966A2/en
Publication of JP2011506497A publication Critical patent/JP2011506497A/ja
Publication of JP2011506497A5 publication Critical patent/JP2011506497A5/ja
Pending legal-status Critical Current

Links

JP2010538345A 2007-12-19 2008-12-18 RhoCに基づく免疫療法 Pending JP2011506497A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200701844 2007-12-19
PCT/DK2008/050324 WO2009076966A2 (en) 2007-12-19 2008-12-18 Rhoc-based immunotherapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014027157A Division JP5813801B2 (ja) 2007-12-19 2014-02-17 RhoCに基づく免疫療法

Publications (2)

Publication Number Publication Date
JP2011506497A JP2011506497A (ja) 2011-03-03
JP2011506497A5 true JP2011506497A5 (enExample) 2012-01-12

Family

ID=59270757

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2010538345A Pending JP2011506497A (ja) 2007-12-19 2008-12-18 RhoCに基づく免疫療法
JP2014027157A Active JP5813801B2 (ja) 2007-12-19 2014-02-17 RhoCに基づく免疫療法
JP2015182828A Active JP6084671B2 (ja) 2007-12-19 2015-09-16 RhoCに基づく免疫療法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2014027157A Active JP5813801B2 (ja) 2007-12-19 2014-02-17 RhoCに基づく免疫療法
JP2015182828A Active JP6084671B2 (ja) 2007-12-19 2015-09-16 RhoCに基づく免疫療法

Country Status (9)

Country Link
US (3) US9163077B2 (enExample)
EP (1) EP2234635B1 (enExample)
JP (3) JP2011506497A (enExample)
AU (1) AU2008338063B2 (enExample)
CA (1) CA2710061C (enExample)
DK (1) DK2234635T3 (enExample)
ES (1) ES2623447T3 (enExample)
PL (1) PL2234635T3 (enExample)
WO (1) WO2009076966A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2710061C (en) * 2007-12-19 2022-07-12 Rhovac Aps Rhoc-based immunotherapy
US10019634B2 (en) * 2010-06-04 2018-07-10 Masoud Vaziri Method and apparatus for an eye tracking wearable computer
US20190382454A1 (en) * 2015-03-05 2019-12-19 Amrita Therapeutics Limited A modified peptide as an anticancer agent
WO2019094326A1 (en) 2017-11-08 2019-05-16 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating cancer using rhoa dominant negative forms
KR101947452B1 (ko) * 2018-04-26 2019-02-13 주식회사 에스와이테크 하이브리드 acp 시스템 및 그 제조방법
KR200488051Y1 (ko) * 2018-05-28 2018-12-07 주식회사 에스와이테크 완충 z-바
WO2022017895A1 (en) 2020-07-21 2022-01-27 Rhovac Aps Treatment of residual disease

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003040165A2 (en) * 2000-10-19 2003-05-15 Epimmune Inc. Hla class i and ii binding peptides and their uses
JP2001526914A (ja) * 1997-12-31 2001-12-25 インサイト・ファーマスーティカルズ・インコーポレイテッド ヒト・調節タンパク質
US6814968B1 (en) * 1998-06-04 2004-11-09 Vanderbilt University Inhibition of viral infection and spread with viral and RhoA-derived peptides
US20030039635A1 (en) * 1998-09-30 2003-02-27 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
AU2088801A (en) 1999-12-10 2001-06-18 Dana-Farber Cancer Institute, Inc. Metastasis genes and uses thereof
US7939087B2 (en) * 2000-10-27 2011-05-10 Novartis Vaccines And Diagnostics, Inc. Nucleic acids and proteins from Streptococcus groups A & B
WO2003008537A2 (en) * 2001-04-06 2003-01-30 Mannkind Corporation Epitope sequences
US7194802B2 (en) * 2002-03-26 2007-03-27 Seagate Technology Llc Tool for certifying a head-gimbal assembly
DE10217035A1 (de) * 2002-04-11 2004-01-22 Universitätsklinikum Charité Medizinische Fakultät der Humboldt-Universität Akademische Verwaltung - Forschung Rekrutierungsmodule von RhoA und RhoC
WO2005017160A2 (en) * 2003-08-13 2005-02-24 Children's Hospital Medical Center Mobilization of hematopoietic cells
US7960100B1 (en) * 2004-04-30 2011-06-14 Celera Corporation Colon cancer targets and uses thereof
US7763418B2 (en) * 2005-07-05 2010-07-27 Cytoskeleton, Inc. Detection of Rho proteins
CA2710061C (en) * 2007-12-19 2022-07-12 Rhovac Aps Rhoc-based immunotherapy

Similar Documents

Publication Publication Date Title
RU2753246C2 (ru) Составы вакцин против неоплазии и способы их получения
JP6943545B2 (ja) 腫瘍特異的なネオ抗原を同定する組成物および方法
CN105025932B (zh) 癌疫苗及使用其的治疗方法
TWI504407B (zh) 癌疫苗組合物
US8263560B2 (en) HPV 16 peptide vaccine for head and neck cancer
US20160022791A1 (en) Cytotoxic T Lymphocyte Inducing Immunogens For Prevention Treatment and Diagnosis of Cancer
JP2007511547A5 (enExample)
JP2006526628A (ja) Hla−a2腫瘍関連抗原ペプチドおよび組成物
CN101796070A (zh) p53肽疫苗
JP6406647B2 (ja) 細胞性免疫誘導ワクチン
JP2022538609A5 (enExample)
JP2022514116A5 (enExample)
JP2014139185A5 (enExample)
KR101810840B1 (ko) 암의 예방 및 치료용 msi-특이적 프레임쉬프트 펩티드(fsp)
CN112867502A (zh) Herv-k衍生抗原作为共有肿瘤抗原用于抗癌疫苗
WO2017177907A1 (zh) 抗免疫检查点pd-l1和pd-l2肿瘤疫苗
WO2017177908A1 (zh) Pd-l1和pd-l2重组蛋白及其用途
Velders et al. Identification of peptides for immunotherapy of cancer. It is still worth the effort
EP3169354A2 (en) Identification of immunogenic mhc class ii peptides for immune-based therapy
US10286050B2 (en) Multi-epitope TARP peptide vaccine and uses thereof
US11191828B2 (en) MHC class I associated hepatitis B peptides
JPWO2015005479A1 (ja) 腫瘍抗原ペプチド
CN108250266A (zh) 一种hla-a11限制性gpc3源性多肽及包含它的疫苗
De Leo p53-based immunotherapy of cancer
Ressing et al. Vaccination Strategies to Induce T-Cell Immunity Against Tumours